# A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Source: https://onco.cc/trials/nct04481763/  
OnCo record `nct04481763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of camrelizumab in triple-negative breast cancer, run by Jiangxi Provincial Cancer Hospital, now recruiting.

## Summary

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast is a phase 1/2, interventional study registered as NCT04481763 by Jiangxi Provincial Cancer Hospital, with a registry enrolment figure of 20 participants, started 2020-07-14 and due to reach its primary completion in 2024-08-30. Interventions recorded: Camrelizumab; radiotherapy. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants with a histological or cytological diagnosis of TNBC breast cancer , defined by ER \<1%, PR \<1% and HER2 negative on IHC and/or non-amplified by ISH by local lab testing". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04481763
- Phase: 1/2
- Setting: A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
- Sponsor: Jiangxi Provincial Cancer Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT04481763: https://clinicaltrials.gov/study/NCT04481763

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04481763.json